Voriconazole brain tissue levels in rhinocerebral aspergillosis in a successfully treated young woman

International Journal of Antimicrobial Agents

Volumn 28, Issue 3, 2006, Pages 262-265

  Elter, Thomas ^a   Sieniawski, Michal ^a   Gossmann, Axel ^a   Wickenhauser, Claudia ^a   Schröder, Ursula ^a   Seifert, Harald ^a   Kuchta, Johannes ^a   Burhenne, Jürgen ^b   Riedel, Klaus Dieter ^b   Fätkenheuer, Gerd ^a   Cornely, Oliver A ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Intracerebral abscess; Rhinocerebral aspergillosis; Voriconazole level

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; ANTIFUNGAL AGENT; ANTIINFECTIVE AGENT; CASPOFUNGIN; FLUCLOXACILLIN; FOSFOMYCIN; PREDNISONE; VORICONAZOLE;

ADULT; ANAMNESIS; ARTICLE; ASPERGILLOSIS; ASPERGILLUS FUMIGATUS; BRAIN ABSCESS; BRAIN TISSUE; CASE REPORT; CENTRAL NERVOUS SYSTEM; DRUG BRAIN LEVEL; FEMALE; HUMAN; HUMAN TISSUE; LABORATORY TEST; MORTALITY; MYCOSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PHYSICAL EXAMINATION; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; TREATMENT OUTCOME;

ADULT; AMPHOTERICIN B; ANTIFUNGAL AGENTS; ARTHRITIS; ASPERGILLUS FUMIGATUS; BRAIN; BRAIN ABSCESS; CHROMATOGRAPHY, LIQUID; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MASS SPECTROMETRY; NEUROASPERGILLOSIS; PARANASAL SINUS DISEASES; PEPTIDES, CYCLIC; PYRIMIDINES; STAPHYLOCOCCUS AUREUS; TRIAZOLES;

EID: 33747133236     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2006.04.006     Document Type: Article

References (16)

1. Pennick G.J., Clark M., Sutton D.A., and Rinaldi M.G. Development and validation of a high performance liquid chromatography assay for voriconazole. Antimicrob Agents Chemother 47 (2003) 2348-2350
2. Walsh T.J., Hier D.B., and Caplan L.R. Aspergillosis of the central nervous system: clinicopathological analysis of 17 patients. Ann Neurol 18 (1985) 574-582
3. Boes B., Bashir R., Boes C., Hahn F., McConnell J.R., and McComb R. Central nervous system aspergillosis. Analysis of 26 patients. J Neuroimaging 4 (1994) 123-129
4. Bodey G., Bueltmann B., Duguid W., et al. Fungal infections in cancer patients: an international autopsy survey. Eur J Clin Microbiol Infect Dis 11 (1992) 99-109
5. Denning D.W., and Stevens D.A. Antifungal and surgical treatment of invasive aspergillosis: review of 2,121 published cases. Rev Infect Dis 12 (1990) 1147-1201
6. Denning D.W. Therapeutic outcome in invasive aspergillosis. Clin Infect Dis 23 (1996) 608-615
7. Stevens D.A., Kan V.L., Judson M.A., et al. Practice guidelines for diseases caused by Aspergillus. Clin Infect Dis 30 (2000) 696-709
8. Heykants J., Michiels M., and Meuldermans W. The pharmacokinetics of itraconazole in animals and man: an overview. In: Fromtling R. (Ed). Recent trends in the discovery, development and evaluation of antifungal agents. (1987), J.R. Prous Science Publishers, Barcelona, Spain 223-249
9. Collette N., van der Auwera P., Lopez A.P., Heymans C., and Meunier F. Tissue concentrations and bioactivity of amphotericin B in cancer patients treated with amphotericin B-deoxycholate. Antimicrob Agents Chemother 33 (1989) 362-368
10. Patterson T.F., Kirkpatrick W.R., White M., et al. Invasive aspergillosis. Disease spectrum, treatment practices, and outcomes. I3 Aspergillus Study Group. Medicine (Baltimore) 79 (2000) 250-260
11. Collette N., Van der Auwera P., Meunier F., Lambert C., Sculier J.P., and Coune A. Tissue distribution and bioactivity of amphotericin B administered in liposomes to cancer patients. J Antimicrob Chemother 27 (1991) 535-548
12. Hajdu R., Thompson R., Sundelof J.G., et al. Preliminary animal pharmacokinetics of the parenteral antifungal agent MK-0991 (L-743,872). Antimicrob Agents Chemother 41 (1997) 2339-2344
13. Hoffman H.L., and Rathbun R.C. Review of the safety and efficacy of voriconazole. Expert Opin Investig Drugs 11 (2002) 409-429
14. Herbrecht R., Denning D.W., Patterson T.F., et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl Med J 347 (2002) 408-415
15. Schwartz S., Ruhnke M., Ribaud P., et al. Improved outcome in central nervous system aspergillosis, using voriconazole treatment. Blood 106 (2005) 2641-2645
16. Lutsar I., Roffey S., and Troke P. Voriconazole concentrations in the cerebrospinal fluid and brain tissue of guinea pigs and immunocompromised patients. Clin Infect Dis 37 (2003) 728-732